Alzheimer's Disease (eBook)
Understanding Biomarkers, Big Data, and Therapy
eBook Download:
EPUB
2021
|
1. Auflage
254 Seiten
Elsevier Science (Verlag)
978-0-12-821335-3 (ISBN)
254 Seiten
Elsevier Science (Verlag)
978-0-12-821335-3 (ISBN)
Nearly 44 million people have Alzheimer's or related dementia worldwide, according to the Alzheimer's Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer's and other forms of dementia.First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer's disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer's disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer's diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer's disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer's disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. - Reviews recent developments of cognitive and clinical studies - Covers factors underlying the transition from mild cognitive impairment to Alzheimer's disease - Discusses different neural biomarkers underlying the development and treatment of Alzheimer's disease - Provides a comparison of the effectiveness of various types of treatments
Dr. Ahmed Moustafa is a Professor of Psychology and Computational Modeling at School of Psychology, Bond University, Gold Coast, Queensland, Australia. Prior to moving to Bond University, Ahmed was an associate professor in Psychology and Neuroscience at Marcs Institute for Brain, Behavior, and Development & School of Psychology, Western Sydney University. Ahmed is trained in computer science, psychology, neuroscience, and cognitive science. His early training took place at Cairo University in mathematics and computer science. Before joining Western Sydney University as a lab director, Ahmed spent 11 years in America working on several psychology and neuroscience projects. Ahmed conducts research on computational and neuropsychological studies of addiction, schizophrenia, Parkinson's disease, PTSD, depression, Alzheimer's disease. He has published over 240 papers in high-ranking journals including Science, PNAS, Journal of Neuroscience, Brain, Neuroscience and Biobehavioral Reviews, Nature (Parkinson's disease), Neuron, among others. Ahmed has obtained grant funding from Australia, USA, Qatar, UAE, Turkey, and other countries. Ahmed has recently published ten books: (1) Computational models of brain and behavior; (2) Social Cognition in Psychosis, (3) computational Neuroscience Models of the Basal Ganglia, (4) Cognitive, Clinical, and Neural Aspects of Drug Addiction; (5) The Nature of Depression: An updated review; (6) Big data in psychiatry and neurology; (7) Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy. Elsevier; (8) Cognitive and Behavioral Dysfunction in Schizophrenia; (9) Female Pioneers from Ancient Egypt and the Middle East; and (10) Mental health effects of COVID-19. In the last 10 years, Ahmed has published collaboratively with 71 colleagues, has more than 510 co-authors, from 35 institutions in 14 countries. Ahmed is now Editor-in-Chief of Discover Psychology, a new journal by Springer Nature.
Nearly 44 million people have Alzheimer's or related dementia worldwide, according to the Alzheimer's Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer's and other forms of dementia.First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer's disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer's disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer's diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer's disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer's disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. - Reviews recent developments of cognitive and clinical studies- Covers factors underlying the transition from mild cognitive impairment to Alzheimer's disease- Discusses different neural biomarkers underlying the development and treatment of Alzheimer's disease- Provides a comparison of the effectiveness of various types of treatments
Dr. Ahmed Moustafa is a Professor of Psychology and Computational Modeling at School of Psychology, Bond University, Gold Coast, Queensland, Australia. Prior to moving to Bond University, Ahmed was an associate professor in Psychology and Neuroscience at Marcs Institute for Brain, Behavior, and Development & School of Psychology, Western Sydney University. Ahmed is trained in computer science, psychology, neuroscience, and cognitive science. His early training took place at Cairo University in mathematics and computer science. Before joining Western Sydney University as a lab director, Ahmed spent 11 years in America working on several psychology and neuroscience projects. Ahmed conducts research on computational and neuropsychological studies of addiction, schizophrenia, Parkinson's disease, PTSD, depression, Alzheimer's disease. He has published over 240 papers in high-ranking journals including Science, PNAS, Journal of Neuroscience, Brain, Neuroscience and Biobehavioral Reviews, Nature (Parkinson's disease), Neuron, among others. Ahmed has obtained grant funding from Australia, USA, Qatar, UAE, Turkey, and other countries. Ahmed has recently published ten books: (1) Computational models of brain and behavior; (2) Social Cognition in Psychosis, (3) computational Neuroscience Models of the Basal Ganglia, (4) Cognitive, Clinical, and Neural Aspects of Drug Addiction; (5) The Nature of Depression: An updated review; (6) Big data in psychiatry and neurology; (7) Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy. Elsevier; (8) Cognitive and Behavioral Dysfunction in Schizophrenia; (9) Female Pioneers from Ancient Egypt and the Middle East; and (10) Mental health effects of COVID-19. In the last 10 years, Ahmed has published collaboratively with 71 colleagues, has more than 510 co-authors, from 35 institutions in 14 countries. Ahmed is now Editor-in-Chief of Discover Psychology, a new journal by Springer Nature.
Nearly 44 million people have Alzheimer's or related dementia worldwide, according to the Alzheimer's Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer's and other forms of dementia.First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer's disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer's disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer's diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer's disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer's disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. - Reviews recent developments of cognitive and clinical studies- Covers factors underlying the transition from mild cognitive impairment to Alzheimer's disease- Discusses different neural biomarkers underlying the development and treatment of Alzheimer's disease- Provides a comparison of the effectiveness of various types of treatments
| Erscheint lt. Verlag | 28.8.2021 |
|---|---|
| Sprache | englisch |
| Themenwelt | Geisteswissenschaften ► Psychologie ► Allgemeine Psychologie |
| Geisteswissenschaften ► Psychologie ► Biopsychologie / Neurowissenschaften | |
| Geisteswissenschaften ► Psychologie ► Klinische Psychologie | |
| Geisteswissenschaften ► Psychologie ► Verhaltenstherapie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Neurologie | |
| Naturwissenschaften ► Biologie ► Humanbiologie | |
| Naturwissenschaften ► Biologie ► Zoologie | |
| ISBN-10 | 0-12-821335-3 / 0128213353 |
| ISBN-13 | 978-0-12-821335-3 / 9780128213353 |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
EPUB (Adobe DRM)Größe: 2,7 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
Mehr entdecken
aus dem Bereich
aus dem Bereich
Psychotherapien wirksam gestalten
eBook Download (2013)
Klett-Cotta (Verlag)
CHF 37,95
Psychotherapien wirksam gestalten
eBook Download (2014)
Klett-Cotta (Verlag)
CHF 37,95
Diagnostik und Behandlung von Folgen schwerer Gewalt und …
eBook Download (2022)
Schattauer (Verlag)
CHF 85,95
